1. Home
  2. HOWL vs GAN Comparison

HOWL vs GAN Comparison

Compare HOWL & GAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • GAN
  • Stock Information
  • Founded
  • HOWL 2017
  • GAN 1999
  • Country
  • HOWL United States
  • GAN United States
  • Employees
  • HOWL N/A
  • GAN N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • GAN Computer Software: Programming Data Processing
  • Sector
  • HOWL Health Care
  • GAN Technology
  • Exchange
  • HOWL Nasdaq
  • GAN Nasdaq
  • Market Cap
  • HOWL 87.4M
  • GAN 83.2M
  • IPO Year
  • HOWL 2021
  • GAN 2020
  • Fundamental
  • Price
  • HOWL $1.36
  • GAN $1.83
  • Analyst Decision
  • HOWL Strong Buy
  • GAN
  • Analyst Count
  • HOWL 2
  • GAN 0
  • Target Price
  • HOWL $9.50
  • GAN N/A
  • AVG Volume (30 Days)
  • HOWL 263.3K
  • GAN 233.8K
  • Earning Date
  • HOWL 03-06-2025
  • GAN 03-12-2025
  • Dividend Yield
  • HOWL N/A
  • GAN N/A
  • EPS Growth
  • HOWL N/A
  • GAN N/A
  • EPS
  • HOWL N/A
  • GAN N/A
  • Revenue
  • HOWL $3,386,000.00
  • GAN $134,024,000.00
  • Revenue This Year
  • HOWL N/A
  • GAN $5.97
  • Revenue Next Year
  • HOWL $34.17
  • GAN $11.32
  • P/E Ratio
  • HOWL N/A
  • GAN N/A
  • Revenue Growth
  • HOWL N/A
  • GAN N/A
  • 52 Week Low
  • HOWL $1.26
  • GAN $1.17
  • 52 Week High
  • HOWL $8.19
  • GAN $1.90
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 41.40
  • GAN 36.63
  • Support Level
  • HOWL $1.26
  • GAN $1.72
  • Resistance Level
  • HOWL $1.45
  • GAN $1.85
  • Average True Range (ATR)
  • HOWL 0.09
  • GAN 0.03
  • MACD
  • HOWL 0.02
  • GAN -0.01
  • Stochastic Oscillator
  • HOWL 45.45
  • GAN 38.89

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About GAN GAN Limited

GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.

Share on Social Networks: